What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.06%
Annual Rate
CNY 0.28Paid annual
Payout Ratio
96.2%High
Last Ex-Dividend
Jun 22, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
23.65BCNY
3.52B · vs all stocks (USD)
Updated Aug 21, 2026
Revenue (TTM)
731.72MCNY
108.81M · vs all stocks (USD)
Updated Aug 21, 2026
Profit Margin
2.54%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Beta
0.5100x
vs all stocks
Updated Aug 21, 2026
52-Week Change
2.25%
vs all stocks
Updated Aug 21, 2026
Market Capitalization
23.65BCNY
3.52B · vs all stocks (USD)
Updated Aug 21, 2026
Enterprise Value
24.20BCNY
3.60B · vs all stocks (USD)
Updated Aug 21, 2026
Forward P/E
225.74x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Price to Sales (TTM)
33.23x
vs Scientific & Technical Instruments peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 32.32×.Updated Aug 21, 2026
Price to Book (MRQ)
19.24x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Enterprise to Revenue
33.07x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Gross Margin
40.36%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Profit Margin
2.54%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Operating Margin
0.87%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Return on Assets (TTM)
0.93%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Return on Equity (TTM)
1.52%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Revenue (TTM)
731.72MCNY
108.81M · vs all stocks (USD)
Updated Aug 21, 2026
Revenue per Share (TTM)
13.92CNYUpdated Aug 21, 2026
Quarterly Revenue Growth
28.60%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Gross Profit (TTM)
291.22MCNY
43.31M · vs all stocks (USD)
Updated Aug 21, 2026
EBITDA (TTM)
71.56MCNY
10.64M · vs all stocks (USD)
Updated Aug 21, 2026
Net Income (TTM)
18.58MCNY
2.76M · vs all stocks (USD)
Updated Aug 21, 2026
Quarterly Earnings Growth (YoY)
43.52%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Operating Cash Flow (TTM)
41.83MCNY
6.22M · vs all stocks (USD)
Updated Aug 21, 2026
Levered Free Cash Flow (TTM)
-247.94MCNY
-36.87M · vs all stocks (USD)
Updated Aug 21, 2026
Trailing Annual Dividend Rate
0.2800CNYUpdated Aug 21, 2026
Trailing Annual Dividend Yield
0.06%
vs all stocks
Updated Aug 21, 2026
Payout Ratio
96.18%
vs Scientific & Technical Instruments peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 75.68%.Updated Aug 21, 2026
Revenue
691.01MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
368.24MCNYFY2025 · Dec 31, 2025
Gross Profit
322.77MCNYFY2025 · Dec 31, 2025
Operating Income
94.90MCNY
14.11M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
51.66MCNYFY2025 · Dec 31, 2025
Income Tax Expense
5.33MCNYFY2025 · Dec 31, 2025
Net Income
46.33MCNYFY2025 · Dec 31, 2025
EBIT
58.48MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
168.78MCNYFY2025 · Dec 31, 2025
Research & Development
82.07MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
39.59MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
9.25MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
1.34MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
6.82MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.8816CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.8816CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
52.55MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
52.55MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
46.33MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-118.86MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-299.71MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
267.13MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
46.33MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
13.23MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-93.16MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-85.26MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-180.85MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-1.07BCNYFY2025 · Dec 31, 2025
Sale of Investments
710.08MCNYFY2025 · Dec 31, 2025
Other Investing Activity
-1.00MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-541.77MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
783.26MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-199.98MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-21.06MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-7.49MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
554.74MCNYFY2025 · Dec 31, 2025
Shares Outstanding
52.80MSharesUpdated Aug 21, 2026
Float Shares
18.23MSharesUpdated Aug 21, 2026
% Held by Insiders
65.03%
vs all stocks
Updated Aug 21, 2026
% Held by Institutions
9.11%
vs all stocks
Updated Aug 21, 2026
Total Cash (MRQ)
664.88MCNY
98.87M · vs all stocks (USD)
Updated Aug 21, 2026
Total Cash per Share (MRQ)
12.65CNYUpdated Aug 21, 2026
Total Debt (MRQ)
689.82MCNY
102.58M · vs all stocks (USD)
Updated Aug 21, 2026
Total Debt to Equity (MRQ)
0.5484x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Current Ratio (MRQ)
3.59x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Book Value per Share (MRQ)
23.93CNYUpdated Aug 21, 2026
Total Assets
2.14BCNY
317.61M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.27BCNYFY2025 · Dec 31, 2025
Total Liabilities
868.08MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
868.78MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
551.36MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
316.72MCNYFY2025 · Dec 31, 2025
Cash
267.13MCNYFY2025 · Dec 31, 2025
Cash Equivalents
5.59MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
272.71MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
383.19MCNYFY2025 · Dec 31, 2025
Accounts Receivable
182.47MCNYFY2025 · Dec 31, 2025
Inventory
244.71MCNYFY2025 · Dec 31, 2025
Accounts Payable
143.54MCNYFY2025 · Dec 31, 2025
Short-term Debt
105.56MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
14.80MCNYFY2025 · Dec 31, 2025
Long-term Debt
527.79MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
52.80MCNYFY2025 · Dec 31, 2025
Retained Earnings
258.03MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.27BCNY
188.52M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
26.93MCNYFY2025 · Dec 31, 2025
52-Week Low
286.10CNYUpdated Aug 21, 2026
52-Week High
709.49CNYUpdated Aug 21, 2026
52-Week Change
2.25%
vs all stocks
Updated Aug 21, 2026
Beta
0.5100x
vs all stocks
Updated Aug 21, 2026
50-Day MA
472.77CNYUpdated Aug 21, 2026
200-Day MA
415.36CNYUpdated Aug 21, 2026
Avg 10-Day Volume
2.02MSharesUpdated Aug 21, 2026
Avg 30-Day Volume
2.30MSharesUpdated Aug 21, 2026
Diluted EPS (TTM)
0.3700CNYUpdated Aug 21, 2026
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 19.24×, higher than 95% of its Scientific & Technical Instruments peers (median 5.25×)Significant
Partial Recovery After Sharp DeclineMulti-Year Revenue, Profit, And Income GrowthUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Partial Recovery After Sharp DeclineMulti-Year Revenue, Profit, And Income GrowthUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Partial Recovery After Sharp DeclineMulti-Year Revenue, Profit, And Income GrowthUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated